A study assessing 11 long-term survivors with extensive-stage SCLC suggests that alterations in MLL2 may predict better survival outcomes for patients undergoing first-line chemoimmunotherapy [57]. This evidence concerns the gene KMT2B and small cell lung carcinoma.